VolitionRx boosts cash reserves in 1Q, inks distribution deal with Active Motif

The life-sciences company inked a distribution deal with rival Active Motif that paves the way for the sale of its research-use-only (RUO) kits

A medical researcher working in a lab
VolitionRx's cancer-screening tools have high demand

Cancer test specialist VolitionRx Ltd (NYSEMKTS:VNRX) reported a slower first quarter cash burn rate on Thursday while growing cash reserves.

For the quarter ended March 31, the life-sciences company said that it increased its cash and equivalents to US$14.3mln, compared to US$10.1mln in the previous quarter.

"We have made great progress this quarter, moving our clinical assay development strongly forward and broadening our potential revenue base with our recently announced exclusive global license, manufacturing, sales and distribution agreement with Active Motif for a range of research use only kits," said Volition’s CEO Cameron Reynolds.

"We look forward to achieving our numerous upcoming clinical and commercial milestones, while continuing to keep close control on our cash burn, which has remained relatively stable."

VolitionRx has entered into a groundbreaking sales and distribution partnership with a rival life sciences group Active Motif that will pave the way for the sale of a range of research-use-only (RUO) kits based on its proprietary Nucleosomics technology starting in June.

READ: VolitionRx signs distribution agreement with Active Motif to sell research-use-only kits

These research-use-only kits are based on VolitionRx’s technology platform of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.

Once they are distributed with the help of Active Motif, these RUO kits will provide researchers with new ways to explore changes in gene expression across different diseases from clinical samples.

The RUO kits are based on the same Nu.Q immunoassay technology as Volition's cancer screening panels and may be used to investigate a variety of clinical questions beyond Volition's core focus in cancer biomarkers.

Quick facts: VolitionRx

Price: 3.5 USD

Market Cap: $161.79 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...



VolitionRX encouraged by early data on its Nu.QTM blood test as potential...

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds tells Proactive's Andrew Scott they've been investigating how its Nu.QTM platform might be clinically useful as either a diagnostic or prognostic tool for COVID-19 and that they've been encouraged by some of the early data. He says...

on 8/5/20

2 min read